Last updated: March 6, 2026
What is NDC 00187-0063?
NDC 00187-0063 refers to a specific drug product listed under the National Drug Code. According to available databases, this NDC corresponds to Humira (adalimumab) Pen from AbbVie, used primarily to treat autoimmune diseases.
Market Overview
Product Details
| Attribute |
Data |
| Drug Name |
Humira (adalimumab) Pen |
| Manufacturer |
AbbVie |
| Formulation |
Pen injectable |
| Indications |
Rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, hidradenitis suppurativa, uveitis, juvenile idiopathic arthritis |
Market Size and Penetration
- Global market size (2022): Approximately USD 18 billion (IQVIA, 2023).
- US market size (2022): USD 12 billion.
- Market growth rate: CAGR of roughly 8% projected from 2023-2027.
Key Competitors
| Drug Name |
Market Share |
Indications |
| Humira (adalimumab) |
~65% |
Autoimmune, inflammatory diseases |
| Enbrel (etanercept) |
~15% |
Rheumatoid arthritis |
| Stelara (ustekinumab) |
~8% |
Crohn’s disease, psoriasis |
| Others |
~12% |
Various biologics |
Regulatory Landscape
- Patent expiry: Expected in 2023-2024 for U.S. patent exclusivity.
- Biosimilar entry: Multiple biosimilars approved or under review, including Amgen’s Amgevita and Samsung’s Hadlima, approved by the FDA as of mid-2023.
Price Analysis
Current Pricing
| Product Variant |
List Price per Pen (USD) |
Typical Co-pay (USD) |
Reimbursement Rate (%) |
| Humira Pen |
$2,500 - $3,000 |
$5 - $50 |
70-80% |
(Prices vary by insurer, region, and patient assistance programs.)
Historical Trends
- Pre-biologic biosimilar approval: List prices for Humira declined marginally, with discounts of 10-15% per biosimilar.
- Post-patent expiry: Biosimilar competition is expected to reduce list prices by 25-35%.
Biosimilar Impact
- Price reductions forecasted around 30% with increased biosimilar market penetration by 2025.
- Price elasticity suggests demand remains relatively stable despite price shifts.
Price Projections
Short-Term (2023-2025)
- List price stabilization: Expected to hover between $2,500 and $3,000 per pen.
- Biosimilar discounts: Biosimilars will achieve list prices around $1,700 - $2,200.
- Net prices: Net prices to insurers could decline 20-25% due to negotiations and rebates.
Medium to Long-Term (2026-2030)
- Potential further reductions: Biosimilar competition may compress prices an additional 15-20% below 2025 levels.
- Market volume growth: Demand for adalimumab-based therapies is still expected to grow at about 4-6% annually due to expanding indications and increasing prevalence of autoimmune conditions.
- Pricing stabilization: Predicted to plateau around $1,500 - $2,000 per pen, depending on biosimilar market share and payer negotiations.
Regulatory and Market Drivers
| Factor |
Impact |
| Biosimilar approvals |
Decreases list prices, increases market access |
| Healthcare policy changes |
May influence reimbursement rates |
| Patent litigation and legal challenges |
Could delay biosimilar entry or affect pricing |
Key Takeaways
- The product identified by NDC 00187-0063 is Humira Pen, a leading biologic for autoimmune treatments.
- The U.S. market size for Humira was USD 12 billion in 2022, with a stable growth trajectory.
- Patent expirations and biosimilar entries are expected to lower list prices by 25-35% over the next two years.
- Price per pen currently ranges from USD 2,500 to USD 3,000, with net prices falling due to discounts and rebates.
- Projected price reductions with biosimilars suggest an average price of USD 1,700 to USD 2,200 per pen by 2025, stabilizing around USD 1,500 to USD 2,000 long-term.
FAQs
1. How will biosimilar competition affect Humira’s market share?
Biosimilar entry is expected to reduce Humira’s market share from roughly 65% to below 50% by 2025, with biosimilars capturing significant portions of the market.
2. What regulatory changes could impact pricing?
Legislation supporting biosimilar substitution and price negotiation could accelerate price reductions and market shifts.
3. Will demand for Humira decline due to biosimilar availability?
Demand is likely to remain stable or grow modestly due to expanding indications, despite price competition.
4. How do payer negotiations influence actual transaction prices?
Rebates and contracting strategies can reduce effective prices by 20-25%, making net prices significantly lower than list prices.
5. What is the expected timeline for biosimilar approval?
Multiple biosimilars are already approved or under review, with additional approvals anticipated through 2024-2025.
References
[1] IQVIA. (2023). Global Biologics Market Report.
[2] FDA. (2023). Biosimilar Approvals and Regulatory Updates.
[3] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies for Biologics.
[4] Pharma Intelligence. (2023). Biologics and Biosimilars Market Forecasts.
[5] U.S. Patent and Trademark Office. (2023). Patent Expiry Data for Humira.
